BTIG Sticks to Their Buy Rating for Ascentage Pharma Group International Unsponsored ADR (AAPG)

Tip Ranks
2025.12.03 17:27
portai
I'm PortAI, I can summarize articles.

BTIG analyst Justin Zelin maintained a Buy rating for Ascentage Pharma Group International Unsponsored ADR, setting a price target of $50.00. Zelin, a 4-star analyst with an 8.0% average return, focuses on the Healthcare sector. The analyst consensus for Ascentage Pharma is Strong Buy, with a price target consensus of $49.67.

BTIG analyst Justin Zelin maintained a Buy rating on Ascentage Pharma Group International Unsponsored ADR yesterday and set a price target of $50.00.

TipRanks Cyber Monday Sale

  • Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
  • Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

According to TipRanks, Zelin is a 4-star analyst with an average return of 8.0% and a 38.08% success rate. Zelin covers the Healthcare sector, focusing on stocks such as NovaBridge Biosciences, Viking Therapeutics, and IDEAYA Biosciences.

Ascentage Pharma Group International Unsponsored ADR has an analyst consensus of Strong Buy, with a price target consensus of $49.67.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer